retatrutide triple agonist gip glp-1 glucagon Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide vs Tirzepatide π¬ What's
Description
Physiological Reviews , 94 (4), 1279-1327
The major inflammatory mediator interleukin-6 and obesity

Regardless of the method used to produce a compound, the journey from discovery to clinical application of therapeutic peptides is filled with challenges, particularly in production and analytical characterization

[DOI] [PMC free article] [PubMed] [Google Scholar] 13

doi: 10.1210/jc.2017-02006 [DOI] [PubMed] [Google Scholar] 71.Maselli DB, Camilleri M

control, despite matching for baseline BMI/age [27]
